Emily Riser, MD
Neurology · Birmingham, ALNPI 1124115068
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $165,349 of the $231,356 with a category attached, or 71.5%. 54 manufacturers reported payments, led by AstraZeneca at 32.4% of the total. Reporting peaked in 2019 at $107,224 and has fallen 79.4% since, to $22,117 in 2025. Among neurology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,055 payments — averaging $219.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$75K
- Biogen$45K
- TG Therapeutics, Inc.$33K
- EMD Serono, Inc.$31K
- Bristol Myers Squibb$18K
- Genentech USA, Inc.$12K
- plus $17K from 48 others
Across 528 payments — averaging $13,007 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2M
- Genentech, Inc.$1.7M
- Sanofi$1.2M
- TG Therapeutics, Inc.$923K
- EMD Serono, Inc.$624K
- Roche Products Limited$194K
- plus $311K from 4 others
What the payments were for
- Consulting fees$31,28214%
- Speaking & faculty fees$165,34971%
- Travel & lodging$13,6946%
- Food & beverage$20,8049%
- Education$2280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$231,356 in reported general payments places this provider in the 95th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SolirisEculizumab | 30 | $1,595,642 |
| Kesimpta PenOfatumumab | 74 | $682,697 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 114 | $483,139 |
| AubagioTeriflunomide | 39 | $348,551 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 29 | $314,446 |
| CopaxoneGlatiramer Acetate | 49 | $296,771 |
| TysabriNatalizumab | 25 | $204,495 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 17 | $149,814 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 17 | $145,024 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 12 | $119,672 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 26 | $117,096 |
| Glatiramer Acetate | 73 | $102,605 |
| VumerityDiroximel Fumarate | 11 | $99,159 |
| Avonex (4 Pack)Interferon Beta-1a | 12 | $97,384 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 12 | $97,153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris | $74,930 | $1,595,64230 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $46 | $483,139114 claims |
| BiogenTysabri, Vumerity, Avonex (4 Pack) | $45,390 | $401,03848 claims |
| SanofiAubagio | $1,689 | $348,55139 claims |
| Grifols USA, LLCGamunex-C | $73 | $314,44629 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $183 | $296,77149 claims |
| PfizerOctagam, Panzyga | $670 | $269,48529 claims |
| CSL BehringPrivigen | $140 | $117,09626 claims |
| AbbVieUbrelvy | $673 | $14,56814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 neurology providers in Alabama.
Other neurology in Birmingham
- Diane CounceBirmingham$895K
- Wesley KingBirmingham$167K
- Jerzy SzaflarskiBirmingham$164K
- Victor SungBirmingham$138K
- Raymond FaughtBirmingham$99K
- David GeldmacherBirmingham$99K
- David StandaertBirmingham$82K
- Richard DiethelmBirmingham$65K
- Mina LobbousBirmingham$49K
- Harrison WalkerBirmingham$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.